Acorda Therapeutics Inc (ACOR) reported quarterly earnings results on Thursday, Apr-28-2016. The company reported $0.07 earnings per share for the quarter, missing the analyst consensus estimate by $-0.06. Analysts had a consensus of $0.13. The company posted revenue of $115.90 million in the period, compared to analysts expectations of $117.28 million. The company’s revenue was up 16.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.15 EPS.
Many Wall Street Analysts have commented on Acorda Therapeutics Inc. Acorda Therapeutics Inc was Initiated by Goldman to “Sell” on Mar 30, 2016.
Acorda Therapeutics Inc closed down -0.13 points or -0.45% at $28.91 with 3,73,298 shares getting traded on Wednesday. Post opening the session at $28.92, the shares hit an intraday low of $28.45 and an intraday high of $29.44 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Apr 21, 2016, Lorin Randall (director) sold 1,488 shares at $28.68 per share price. According to the SEC, on Jan 6, 2016, Ian F Smith (director) sold 13,231 shares at $42.05 per share price. On Dec 28, 2015, Jane Wasman (President, Intl and GC) sold 10,751 shares at $43.10 per share price, according to the Form-4 filing with the securities and exchange commission.
Acorda Therapeutics Inc. is a biopharmaceutical company engaged in the identification development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Companys markets three United States Food and Drug Administration (FDA)-approved therapies including Ampyra (dalfampridine) Extended Release Tablets 10milligrams a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets FDA-approved as short-acting drugs for the management of spasticity and Qutenza an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders including chronic post-stroke walking deficits (PSWD) Parkinsons disease epilepsy heart failure MS and spinal cord injury.